Clinical trials: Ankylosing Spondylitis (AS)
Ankylosing Spondylitis
Defining Remission With Etanercept in AS in Real Life Clinical Practice
Determine which remission criterion at Month 6 predicts remission at Month 12 the best.
- Trial name
- REACH AS (NCT02202850)
- Testing
- etanercept
- Where
- 29 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
Primary Objective: To assess the long term safety of Sarilumab (SAR153191/REGN88) in participants with ankylosing spondylitis (AS) Secondary Objective: To assess the long term efficacy of Sarilumab (SAR153191/REGN88) in…
- Trial name
- SUSTAIN (NCT01118728)
- Testing
- Sarilumab
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 223 people
- Sponsor
- Sanofi
Ankylosing Spondylitis
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
- Trial name
- NCT03502616
- Testing
- Tofacitinib
- Where
- 99 sites in United States, Australia and 12 more
- Volunteers
- 270 people
- Sponsor
- Pfizer
Ankylosing Spondylitis (AS)
BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 (risankizumab) in adult patients with AS, in order to provide clinical proof of concept and to select dose (s)…
- Trial name
- NCT02047110
- Testing
- risankizumab
- Volunteers
- 159 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.
- Trial name
- NCT01786668
- Testing
- Tofacitinib 2 mg, Tofacitinib 5 mg, Tofacitinib 10 mg
- Where
- 67 sites in United States, Canada and 8 more
- Volunteers
- 208 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.
Patients with Ankylosing spondylitis more frequently discontinue work. This study measures the impact of Enbrel on work participation.
- Trial name
- AS@WORK (NCT01421303)
- Testing
- Enbrel
- Where
- Belgium
- Volunteers
- 80 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.
- Trial name
- NCT00247962
- Testing
- etanercept, sulphasalazine (SSZ)
- Where
- 83 sites in Australia, Austria and 16 more
- Volunteers
- 566 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis, Ankylosing Spondylitis
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
The aim of this post-marketing observational study is to obtain further data on the evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01083693
- Where
- 20 sites in Austria
- Volunteers
- 162 people
- Sponsor
- Abbott
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA
EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries
This is a non-interventional, post-marketing, observational study (PMOS) in which Humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA, Rheumatoid Arthritis (RA
- Trial name
- EviraEAST (NCT01078402)
- Where
- 163 sites in Croatia, Hungary and 5 more
- Volunteers
- 809 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Anklyosing Spondylitis
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
This study assessed the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who were tolerant to or had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor
- Trial name
- MEASURE2 (NCT01649375)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 53 sites in United States, Austria and 11 more
- Volunteers
- 219 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients
Study to assess whether etanercept therapy is able to increase flow-mediated vasodilatation in AS, and whether etanercept can modify the intima-media thickness (IMT) in these patients
- Trial name
- CREST (NCT00910273)
- Testing
- etanercept
- Where
- 4 sites in Italy
- Volunteers
- 34 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Spondylitis Trial of Apremilast for Better Rheumatic Therapy
This study will evaluate the effectiveness of apremilast in AS as measured by improvement in patients' signs and symptoms of the disease and changes in imaging.
- Trial name
- START (NCT00944658)
- Testing
- Apremilast
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Imperial College London
Ankylosing Spondylitis
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
This study aims to provide a holistic assessment of patients receiving etanercept in a real-world setting.
- Trial name
- NCT00544557
- Testing
- Etanercept
- Where
- Germany
- Volunteers
- 1,715 people
- Sponsor
- Pfizer
Ankylosing Spondylitis (AS)
A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs…
- Trial name
- SELECT-AXIS 1 (NCT03178487)
- Testing
- Upadacitinib
- Where
- 101 sites in United States, Australia and 19 more
- Volunteers
- 187 people
- Sponsor
- AbbVie
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo.
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Trial name
- C-AXSPAND (NCT02552212)
- Testing
- Certolizumab Pegol
- Where
- 105 sites in United States, Australia and 7 more
- Volunteers
- 317 people
- Sponsor
- UCB BIOSCIENCES GmbH
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis
This is a study to evaluate the efficacy and safety of different doses of bimekizumab in subjects with active Ankylosing Spondylitis (AS).
- Trial name
- BE AGILE (NCT02963506)
- Testing
- Bimekizumab
- Where
- 74 sites in United States, Bulgaria and 8 more
- Volunteers
- 303 people
- Sponsor
- UCB Biopharma S.P.R.L.
Ankylosing Spondylitis, Axial Spondyloarthritis
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
The primary objective of this study was to assess the proportion of participants in the infliximab plus naproxen arm versus the placebo plus naproxen arm, in a population of participants with moderate-to-severe active axial…
- Trial name
- INFAST (NCT00844805)
- Testing
- Infliximab, Naproxen
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
The primary objective of this post-marketing observational study was to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history; current concomitant…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT01163916
- Where
- 43 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Abbott